Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWNYIE)

Drug Name

Bemarituzumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Gastric adenocarcinoma	2B72	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Fibroblast growth factor-2 (FGF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sucralfate	DMP9HBO	Acne vulgaris	ED80	Approved	[3]
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
DVC1-0101	DMUGBQK	Arteriosclerosis	BD40	Phase 2	[5]
FPA144	DM1EBRK	Bladder cancer	2C94	Phase 1	[6]
TGP-580	DMYN6G0	Neurodegenerative disorder	8A20-8A23	Discontinued in Phase 2	[7]
RG-8803	DMI0CYV	Diabetic retinopathy	9B71.0	Terminated	[8]
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[9]
N,O6-Disulfo-Glucosamine	DMYCV7U	Discovery agent	N.A.	Investigative	[9]
BIBF100	DMUWO6D	Multiple myeloma	2A83	Investigative	[10]
1,4-Dideoxy-O2-Sulfo-Glucuronic Acid	DM9KUQZ	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor-2 (FGF2)	TTGKIED	FGF2_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
4	Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
5	DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
8	US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
9	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.